Imbio PHA (4.0.0) vs ClearRead CT
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your primary need is automated, rapid assessment of cardiac structures from CTPA scans to aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. This tool excels at precisely measuring right and left ventricle diameters, main pulmonary artery, and aorta diameters, and calculating critical RV/LV and PA/Ao ratios to identify potential right ventricular dilation.
View Imbio PHA (4.0.0) →Choose ClearRead CT if…
Choose ClearRead CT if your focus is on enhancing pulmonary nodule detection and performing coronary artery calcification analysis in CT scans. This AI suite provides advanced vessel suppression technology to improve diagnostic accuracy for various nodule types, offers automated nodule tracking, and streamlines workflows for comprehensive lung cancer screening and cardiovascular risk assessment.
View ClearRead CT →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | ClearRead CT |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | On-premise (stand-alone server, virtual machine) and Cloud |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ClearRead CTClearRead CT's patented vessel suppression technology directly enhances the visual clarity of CT scans, making nodule detection significantly easier and faster for radiologists. While Imbio PHA offers rapid, automated measurements and integrates well, ClearRead CT's unique visual intelligence feature provides a more direct and impactful improvement to the radiologist's viewing experience by simplifying complex image interpretation.
Clinical Value
ClearRead CTClearRead CT explicitly claims a '29% reduction in missed actionable nodules' and 'improved detection accuracy,' directly quantifying a significant enhancement in diagnosing a critical condition like lung cancer. While Imbio PHA provides valuable objective data for PE and hypertension risk stratification, ClearRead CT's specific, high-impact clinical outcome for nodule detection demonstrates a more pronounced and measurable clinical advantage.
Pricing & Value
ClearRead CTBoth tools require direct vendor contact for pricing, making transparency low. However, ClearRead CT provides specific, quantifiable benefits such as a '29% reduction in missed actionable nodules' and 'up to 36% reduced reading time.' These metrics offer a clearer basis for assessing potential return on investment and overall value compared to Imbio PHA's more general benefits.
Enterprise Readiness
Imbio PHA (4.0.0)Both tools offer flexible deployment options (Cloud and on-premise) and FDA clearance. However, Imbio PHA explicitly states 'HIPAA compliant (third-party certified by compliancy group)' and confirms a Business Associate Agreement (BAA). ClearRead CT's compliance is stated as 'likely' and requires contacting the vendor, making Imbio PHA's enterprise readiness more transparent and definitively established regarding critical data security and privacy standards.
Innovation
ClearRead CTClearRead CT features 'Patented Vessel Suppression (Clear Visual Intelligence),' which is a unique and innovative approach to enhancing image clarity specifically for pulmonary nodule detection. While Imbio PHA utilizes AI for automated measurements, ClearRead CT's patented technology directly addresses a significant challenge in radiology by improving visual discernment, demonstrating a higher degree of innovation in its core methodology.
Support & Docs
TieNeither the provided structured facts nor general web searches offer specific details regarding the quality, scope, or availability of support and documentation for either Imbio PHA or ClearRead CT. Both are established enterprise-level healthcare AI solutions, suggesting they likely offer standard customer support, but without comparative information, a definitive winner cannot be determined.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | ClearRead CT |
|---|---|---|
| Product Name | Imbio PHA (4.0.0) | ClearRead CT |
| Company | Imbio | RIVERAIN TECHNOLOGIES |
| Primary Clinical Focus | Assesses potential right ventricular dilation and aids in diagnosis/risk stratification of pulmonary embolism and hypertension from CTPA scans. | Enhances pulmonary nodule detection and coronary artery calcification analysis in CT scans. |
| Key Cardiac Feature | Automated measurement of right and left ventricle diameters; Automated measurement of main pulmonary artery and aorta diameters; Calculates RV/LV and PA/Ao ratios. | Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs) |
| Key Pulmonary Feature | Aids in the diagnosis and risk stratification of pulmonary embolism and hypertension. | Pulmonary Nodule Detection (solid, part-solid, ground glass); Nodule Characterization and Measurement; Automated Nodule Tracking and Comparison to Prior Exams. |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI, Oncology AI, Radiology & Imaging AI |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and ClearRead CT.